Biodegradable Implants for Sustained Protein Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic proteins, such as antibodies, to treat ocular and intraarticular conditions require frequent injections, which are inconvenient and can lead to side effects like retinal detachment, toxicity, and short half-lives due to barriers like the blood-retinal barrier, making sustained release challenging.
Innovation Solution
Development of biodegradable polymer matrix-based implants that encapsulate proteins, allowing for controlled and sustained release of biologically active proteins for at least one month, reducing the need for frequent injections by providing a continuous therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intraocular injections are used to deliver therapeutic proteins, then therapeutic levels of protein can be maintained, but patient discomfort, risk of complications (retinal detachment, lens damage, infection), and localized toxicity increase
Solution Approach 1:
The patent uses biodegradable polymer matrices as intermediary carriers to deliver therapeutic proteins. The polymer matrix encapsulates the protein and controls its release over time, eliminating the need for frequent direct injections into the eye. This intermediary system maintains therapeutic levels while avoiding repeated needle punctures that cause patient discomfort and complications.
Solution Approach 2:
The patent employs pre-formulated biodegradable implants containing therapeutic proteins that are implanted once and then release the protein continuously over weeks or months. This preliminary action of single implantation replaces the need for frequent subsequent injections, maintaining therapeutic protein levels while significantly reducing the frequency of administration and associated risks.
2Loss of substance
If high molecular weight compounds are eliminated via the aqueous humor pathway, then they can be cleared from the vitreous, but the vitreal half-life remains short requiring frequent dosing
Solution Approach 1:
The patent creates a continuous release system using biodegradable polymer implants that steadily deliver therapeutic proteins over extended periods. This continuous action compensates for the short vitreal half-life by maintaining a constant supply of protein, ensuring therapeutic levels are sustained despite rapid clearance through the aqueous humor pathway.
Solution Approach 2:
The patent changes the delivery parameter from intermittent high-dose injections to continuous low-dose release through biodegradable matrices. This parameter change extends the effective duration of action by controlling the release kinetics to match the clearance rate, maintaining therapeutic levels throughout the implant's degradation period.
3Reliability
If direct intraocular injection is used to deliver proteins, then therapeutic levels can be achieved quickly, but localized toxicity occurs due to high pulsed concentrations at the lens and other intraocular tissues
Solution Approach 1:
The patent replaces pulsed high-concentration delivery with continuous low-concentration release from biodegradable implants. This continuous action maintains therapeutic protein levels while avoiding the toxic peaks that occur with frequent injections, as the polymer matrix controls release to prevent localized accumulation at sensitive tissues like the lens.
Solution Approach 2:
The patent changes the concentration-time profile from high pulsed concentrations to sustained low concentrations through controlled release from the polymer matrix. This parameter change eliminates localized toxicity by preventing excessive protein accumulation at any single location, while still achieving and maintaining therapeutic levels throughout the treatment period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable implants effectively maintain therapeutic protein levels for extended periods, minimizing side effects and frequency of administration, while ensuring the protein remains biologically active and effective in treating conditions like macular degeneration and intraarticular inflammation.
Implementation Method 1
biodegradable polymer matrix
Implementation Method 2
release of a therapeutically effective amount of biologically active protein
Data Source
AI summary
Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.